134 related articles for article (PubMed ID: 37279146)
1. Clinical and prognostic features associated with anti-Ro52 autoantibodies in connective tissue diseases patients with interstitial lung disease.
Shi X; Pu X; Cao D; Yan T; Ye Q
Clin Exp Rheumatol; 2023 Nov; 41(11):2257-2263. PubMed ID: 37279146
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of anti-Ro52 (TRIM21) antibodies in adult patients with connective tissue diseases.
Decker P; Moulinet T; Lopez B; Dubucquoi S; Bonnotte B; Lakomy D; Revuz S; Luc A; Bittencourt MC; Hachulla E; Jaussaud R
Eur J Intern Med; 2021 Sep; 91():45-52. PubMed ID: 33972152
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of connective tissue disease-associated interstitial lung disease and interstitial pneumonia with autoimmune features.
Tian M; Huang W; Ren F; Luo L; Zhou J; Huang D; Tang L
Clin Rheumatol; 2020 Feb; 39(2):575-583. PubMed ID: 31758424
[TBL] [Abstract][Full Text] [Related]
4. Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease.
Gui X; Shenyun S; Ding H; Wang R; Tong J; Yu M; Zhao T; Ma M; Ding J; Xin X; Qiu Y; Qiu X; Zhang Y; Cao M; Huang M; Cao M; Dai J; Cai H; Xiao Y
Rheumatology (Oxford); 2022 Nov; 61(11):4570-4578. PubMed ID: 35148366
[TBL] [Abstract][Full Text] [Related]
5. Presentations and outcomes of interstitial lung disease and the anti-Ro52 autoantibody.
Sclafani A; D'Silva KM; Little BP; Miloslavsky EM; Locascio JJ; Sharma A; Montesi SB
Respir Res; 2019 Nov; 20(1):256. PubMed ID: 31718649
[TBL] [Abstract][Full Text] [Related]
6. Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis-an exploratory study.
Hamberg V; Sohrabian A; Volkmann ER; Wildt M; Löfdahl A; Wuttge DM; Hesselstrand R; Dellgren G; Westergren-Thorsson G; Rönnelid J; Andréasson K
Arthritis Res Ther; 2023 Sep; 25(1):162. PubMed ID: 37667402
[TBL] [Abstract][Full Text] [Related]
7. Autoantibodies reactive to PEP08 are clinically related with morbidity and severity of interstitial lung disease in connective tissue diseases.
Okumura M; Ozawa T; Hamana H; Norimatsu Y; Tsuda R; Kobayashi E; Shinoda K; Taki H; Tobe K; Imura J; Sugiyama E; Kishi H; Muraguchi A
Eur J Immunol; 2018 Oct; 48(10):1717-1727. PubMed ID: 29989658
[TBL] [Abstract][Full Text] [Related]
8. Anti-ro52 antibodies and interstitial lung disease in connective tissue diseases excluding scleroderma.
Ferreira JP; Almeida I; Marinho A; Cerveira C; Vasconcelos C
ISRN Rheumatol; 2012; 2012():415272. PubMed ID: 22567412
[TBL] [Abstract][Full Text] [Related]
9. Coexistence of Anti-Ro52 Antibodies in Anti-MDA5 Antibody-Positive Dermatomyositis Is Highly Associated With Rapidly Progressive Interstitial Lung Disease and Mortality Risk.
Lv C; You H; Xu L; Wang L; Yuan F; Li J; Wu M; Zhou S; Da Z; Qian J; Wei H; Yan W; Zhou L; Wang Y; Yin S; Zhou D; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Zang Y; Liu H; Ren T; Wang F; Zhang M; Tan W
J Rheumatol; 2023 Feb; 50(2):219-226. PubMed ID: 35705235
[TBL] [Abstract][Full Text] [Related]
10. Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis.
Xing X; Li A; Li C
Respir Med; 2020 Oct; 172():106134. PubMed ID: 32905890
[TBL] [Abstract][Full Text] [Related]
11. Anti-Ro52 antibodies are a risk factor for interstitial lung disease in primary Sjögren syndrome.
Buvry C; Cassagnes L; Tekath M; Artigues M; Pereira B; Rieu V; Le Guenno G; Tournadre A; Ruivard M; Grobost V
Respir Med; 2020 Mar; 163():105895. PubMed ID: 32056839
[TBL] [Abstract][Full Text] [Related]
12. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
[TBL] [Abstract][Full Text] [Related]
13. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease.
Xu A; Ye Y; Fu Q; Lian X; Chen S; Guo Q; Lu LJ; Dai M; Lv X; Bao C
Rheumatology (Oxford); 2021 Jul; 60(7):3343-3351. PubMed ID: 33331866
[TBL] [Abstract][Full Text] [Related]
14. Comparison of clinical courses and mortality of connective tissue disease-associated interstitial pneumonias and chronic fibrosing idiopathic interstitial pneumonias.
Yıldırım F; Türk M; Bitik B; Erbaş G; Köktürk N; Haznedaroğlu Ş; Türktaş H
Kaohsiung J Med Sci; 2019 Jun; 35(6):365-372. PubMed ID: 30913371
[TBL] [Abstract][Full Text] [Related]
15. Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis.
Vojinovic T; Cavazzana I; Ceruti P; Fredi M; Modina D; Berlendis M; Franceschini F
Clin Rev Allergy Immunol; 2021 Feb; 60(1):87-94. PubMed ID: 33141387
[TBL] [Abstract][Full Text] [Related]
16. Idiopathic Interstitial Pneumonia Associated With Autoantibodies: A Large Case Series Followed Over 1 Year.
Collins BF; Spiekerman CF; Shaw MA; Ho LA; Hayes J; Spada CA; Stamato CM; Raghu G
Chest; 2017 Jul; 152(1):103-112. PubMed ID: 28300570
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of rheumatoid factor and anti-citrullinated peptides in fibrotic interstitial lung disease.
Zheng B; Donohoe K; Hambly N; Johannson KA; Assayag D; Fisher JH; Manganas H; Marcoux V; Khalil N; Kolb M; Ryerson CJ;
Respirology; 2022 Oct; 27(10):854-862. PubMed ID: 35652240
[TBL] [Abstract][Full Text] [Related]
18. Mean pulmonary arterial pressure as a prognostic indicator in connective tissue disease associated with interstitial lung disease: a retrospective cohort study.
Takahashi K; Taniguchi H; Ando M; Sakamoto K; Kondoh Y; Watanabe N; Kimura T; Kataoka K; Suzuki A; Ito S; Hasegawa Y
BMC Pulm Med; 2016 Apr; 16(1):55. PubMed ID: 27094018
[TBL] [Abstract][Full Text] [Related]
19. Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival.
Wodkowski M; Hudson M; Proudman S; Walker J; Stevens W; Nikpour M; Assassi S; Mayes MD; Wang M; Baron M; Fritzler MJ; ; ;
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S131-5. PubMed ID: 26315678
[TBL] [Abstract][Full Text] [Related]
20. Predictors for progressive fibrosis in patients with connective tissue disease associated interstitial lung diseases.
Chiu YH; Spierings J; de Jong PA; Hoesein FM; Grutters JC; van Laar JM; Voortman M
Respir Med; 2021 Oct; 187():106579. PubMed ID: 34438351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
